Cipla Ltd (IN:CIPLA)
:CIPLA
Want to see IN:CIPLA full AI Analyst Report?
CIPLA Stock Chart & Stats
₹1519.30
-₹4.60(-0.31%)
At close: 4:00 PM EST
₹1519.30
-₹4.60(-0.31%)
Day’s Range― - ―
52-Week Range₹1,165.55 - ₹1,672.20
Previous CloseN/A
Volume574.74K
Average Volume (3M)41.77K
Market Cap
₹1.05T
Enterprise Value₹1.06T
Total Cash (Recent Filing)₹83.35B
Total Debt (Recent Filing)₹4.67B
Price to Earnings (P/E)45.1
Beta0.70
Next Earnings
May 13, 2026EPS Estimate
9.8Next Dividend Ex-DateN/A
Dividend Yield0.87%
Share Statistics
EPS (TTM)8.36
Shares Outstanding807,782,650
10 Day Avg. Volume63,362
30 Day Avg. Volume41,773
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)3.74
Price to Sales (P/S)4.28
P/FCF Ratio30.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.67
Revenue Forecast (FY)₹308.51B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseExtremely low leverage and a high equity ratio provide durable financial flexibility. This reduces refinancing and interest risk, supports sustained R&D, capex and M&A capacity, and makes the company more resilient to product delays or cyclical revenue downturns over months to years.
Strong Cash GenerationHigh free cash flow growth and near-1:1 conversion of profits to cash enable repeatable funding for reinvestment, working capital and shareholder returns without raising debt. Consistent cash generation supports strategic initiatives and absorbs regulatory or market shocks long term.
Robust Margins & ProfitabilitySustained high gross and net margins indicate efficient manufacturing and pricing across products. Durable margin structure provides buffer versus pricing pressure in generics, funds therapeutic R&D and commercial investment, and underpins long-run profitability and cash returns.
Bears Say
Negative EPS GrowthDeclining EPS despite revenue growth can reflect margin compression, higher operating or financing costs, or nonrecurring items that erode per‑share earnings. Persistent EPS weakness would limit capital allocation flexibility and dampen long-term shareholder returns if not reversed.
Exposure To Intense Generics CompetitionSignificant exposure to generics subjects revenue and pricing to sustained competitive pressure and tender volatility. Over time this compresses margins, forces higher volumes for growth, and increases dependence on branded or specialty launches to restore durable profitability.
Regulatory & Manufacturing Compliance RiskPharma manufacturing compliance is a structural risk: inspections, remediation or export restrictions can interrupt supply, raise costs and delay launches. Persistent compliance challenges would materially affect revenue streams and international market access over multiple quarters.
Cipla Ltd News
CIPLA FAQ
What was Cipla Ltd’s price range in the past 12 months?
Cipla Ltd lowest stock price was ₹1165.55 and its highest was ₹1672.20 in the past 12 months.
What is Cipla Ltd’s market cap?
Cipla Ltd’s market cap is ₹1.05T.
When is Cipla Ltd’s upcoming earnings report date?
Cipla Ltd’s upcoming earnings report date is May 13, 2026 which is in 15 days.
How were Cipla Ltd’s earnings last quarter?
Cipla Ltd released its earnings results on Jan 23, 2026. The company reported ₹8.36 earnings per share for the quarter, missing the consensus estimate of ₹15.371 by -₹7.011.
Is Cipla Ltd overvalued?
According to Wall Street analysts Cipla Ltd’s price is currently Overvalued.
Does Cipla Ltd pay dividends?
Cipla Ltd pays a Notavailable dividend of ₹16 which represents an annual dividend yield of 0.87%. See more information on Cipla Ltd dividends here
What is Cipla Ltd’s EPS estimate?
Cipla Ltd’s EPS estimate is 9.8.
How many shares outstanding does Cipla Ltd have?
Cipla Ltd has 807,782,650 shares outstanding.
What happened to Cipla Ltd’s price movement after its last earnings report?
Cipla Ltd reported an EPS of ₹8.36 in its last earnings report, missing expectations of ₹15.371. Following the earnings report the stock price went down -4.134%.
Which hedge fund is a major shareholder of Cipla Ltd?
Currently, no hedge funds are holding shares in IN:CIPLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cipla Ltd
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
Technical Analysis
Abbott India Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―
Sanofi India Limited
―